Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Allovir Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ALVR
Nasdaq
8731
https://www.allovir.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Allovir Inc
AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference
- Nov 16th, 2023 12:00 pm
AlloVir Inc (ALVR) Reports Q3 2023 Financial Results
- Nov 2nd, 2023 2:04 pm
AlloVir Reports Third Quarter 2023 Financial Results
- Nov 2nd, 2023 11:00 am
Why AlloVir Stock Dropped Today
- Sep 21st, 2023 6:44 pm
We're Keeping An Eye On AlloVir's (NASDAQ:ALVR) Cash Burn Rate
- Sep 15th, 2023 12:53 pm
These 2 “Strong Buy” Penny Stocks Could Soar to $17 (Or Higher), Say Analysts
- Sep 14th, 2023 1:59 pm
AlloVir to Present at Upcoming Investor Conferences
- Aug 28th, 2023 11:00 am
AlloVir Reports Second Quarter 2023 Financial Results
- Aug 3rd, 2023 11:00 am
Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%
- Jul 21st, 2023 11:17 am
Journey Medical (DERM) to Post Skin Disease Data, Stock Rises 26%
- Jul 4th, 2023 11:34 am
AlloVir, Inc. (ALVR) Upgraded to Buy: Here's Why
- Jun 27th, 2023 4:00 pm
Why Shares of AlloVir Plummeted This Week
- Jun 23rd, 2023 5:56 pm
AlloVir Announces Pricing of Public Offering of Common Stock
- Jun 22nd, 2023 1:20 am
AlloVir Announces Proposed Public Offering of Common Stock
- Jun 21st, 2023 8:18 pm
Why Shares of AlloVir Jumped This Week
- Jun 9th, 2023 3:04 pm
AlloVir Presents Positive Final Results From A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of BK Infection in Kidney Transplant Recipients at the American Transplant Congress (ATC 2023)
- Jun 5th, 2023 11:00 am
AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer
- May 16th, 2023 11:00 am
AlloVir Reports First Quarter 2023 Financial Results
- May 4th, 2023 11:00 am
AlloVir to Present at the BofA Securities 2023 Health Care Conference
- May 1st, 2023 11:00 am
AlloVir's Posoleucel Achieves Non-Relapse Mortality Of 0% In Transplant Patients For Viral Infections
- Apr 26th, 2023 9:12 pm
Scroll